Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.44 |
| ▸ | HTR4 | Q13639 | 10/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2225895 | 0.99 | NR1H4 (0.43) | NR1H4HTR4KCNH2TLR9TLR8 | |
| SCHEMBL12937779 | 0.91 | HTR4 (0.42) | HTR4KCNH2TLR9TLR8TLR7 | |
| SCHEMBL2225012 | 0.84 | NR1H4 (0.40) | NR1H4 | |
| SCHEMBL2224053 | 0.83 | NR1H4 (0.39) | NR1H4 | |
| SCHEMBL2224628 | 0.82 | NR1H4 (0.42) | NR1H4TLR9TLR8TLR7HRH3 | |
| SCHEMBL2226041 | 0.82 | NR1H4 (0.41) | NR1H4TLR9TLR8TLR7HRH3 | |
| SCHEMBL2224511 | 0.82 | NR1H4 (0.68) | NR1H4HTR4KCNH2HRH3 | |
| SCHEMBL12515948 | 0.81 | RARB (0.36) | DRD2DRD3 | |
| SCHEMBL2225963 | 0.81 | NR1H4 (0.67) | NR1H4HTR4KCNH2HRH3 | |
| SCHEMBL2223373 | 0.80 | NR1H4 (0.46) | NR1H4KCNH2DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8907098-B2 | Inhibitors of sphingosine kinase | MERCK PATENT GMBH (DE) | 2014-12-09 | — | — | US | disclosed |
| US-8907098-B2 | Inhibitors of sphingosine kinase | MERCK PATENT GMBH (DE) | 2014-12-09 | — | — | US | disclosed |
| US-8907098-B2 | Inhibitors of sphingosine kinase | MERCK PATENT GMBH (DE) | 2014-12-09 | — | — | US | disclosed |
| EP-2513066-A1 | SPHINGOSINE KINASE INHIBITORS | Merck Patent GmbH (DE) | 2012-10-24 | — | — | EP | disclosed |
| US-20120252815-A1 | INHIBITORS OF SPHINGOSINE KINASE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-10-04 | — | — | US | disclosed |
| US-20120252815-A1 | INHIBITORS OF SPHINGOSINE KINASE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-10-04 | — | — | US | disclosed |
| US-20120252815-A1 | INHIBITORS OF SPHINGOSINE KINASE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-10-04 | — | — | US | disclosed |
| WO-2011082732-A1 | SPHINGOSINE KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252815-A1 | INHIBITORS OF SPHINGOSINE KINASE | SPHK1, S1PR3, SPHK2 | NR1H4 1766/4885HTR4 1542/4885KCNH2 2636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.